News
Find out about what's been happening in the trial.

Fourth investigational arm launched in MND-SMART
Jun 2025: A fourth drug, tacrolimus, has recently been launched in MND-SMART.

MND-SMART Opens in York and Scarborough Hospitals
Jun 2025: York and Scarborough Hospitals are the newest centres to open recruitment to MND-SMART!

MND-SMART launches ‘Davidson Nurses’ programme to expand access to MND Research
Mar 2025: Aligned in our commitment to improve access to research for people living with motor neuron disease, MND-SMART and the Alan Davidson Foundation celebrated a landmark collaboration with the official launch of the ‘Davidson Nurses’ programme.

Christmas Message 2024
Dec 2024: A Christmas message

Interim Analysis Stage 1 – Amantadine – Results
Dec 2024: The Stage 1 interim analysis for amantadine has taken place and the trial committees have decided to continue testing amantadine.

Mr Stevie Morris
Dec 2024: Remembering Mr Stevie Morris for his advocacy and invaluable contributions to MND-SMART through his work as a Patient Advisory Group member.

Memantine, Trazodone and Contemporaneous Placebo – An Unblinding Update
Dec 2024: Final database lock for the discontinued memantine, trazodone and contemporaneous placebo arms has been completed. Former trial participants randomised to these arms can now be unblinded to their treatment allocation.

First results published from innovative platform trial, MND-SMART, aiming to speed up delivery of treatments for motor neuron disease
Sep 2024: Trazodone and memantine results published

Welcome to Sheffield, King's College London and Brighton
Jan 2024: Sheffield, King's College London, and Brighton have recently joined MND-SMART.

Christmas Wishes 2023
Dec 2023: A Christmas video message

Autumn 2023 Newsletter
Nov 2023: Our latest newsletter is now available.

Factors Impacting Trial Participation in People with MND
Oct 2023: MND-SMART researchers have recently published a study that aimed to improve understanding of why people with MND choose to participate, or not participate, in clinical trials of potential new treatments.